Earlier in April, Sun Pharmaceutical said that it had agreed to Ranbaxy from its current owner, Japan's Daiichi Sankyo Co, for $3.2 billion Sun Pharmaceutical Industries Ltd has won US approval to acquire Ranbaxy Laboratories Ltdon condition that it sell its ... India Infoline, 1 month ago
Sun Pharma, Ranbaxy at new high on USFTC conditional nod - Money Control, 1 month ago
Sun-Ranbaxy deal gets FTC nod - Deccan Herald, 1 month ago
Greg Barrett, VP Marketing and Managed Markets at Daiichi Sankyo The partnership between Daiichi Sankyo and Partners HealthCare's Center for Connected Health to bring mobile device monitoring to atrial fibrillation patients is still in its early ...Mobihealthnews, 3 days ago Japan's Daiichi Sankyo revamps operations, management, ahead of olmesartan expiry Fierce CRO, 1 week ago Daiichi Sankyo Company, Ltd Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals (Feb. 17, 2015) Insurance News Net, 1 week ago Daiichi Sankyo Appoints New Group Corporate Officers Noodls, 1 week ago
DAIICHI SANKYO : Details Findings in Organic Research (Synthesis of an alpha-Amylase Inhibitor: Highly Stereoselective Glycosidation and Regioselective...
Daiichi Sankyo Details Findings in Organic Research (Synthesis of an alpha-Amylase Inhibitor: Highly Stereoselective Glycosidation and Regioselective Manipulations of Hydroxyl Groups in Carbohydrate Derivatives) By a News Reporter-Staff News ...4 Traders, 2 days ago Daiichi Sankyo Announces Organizational Restructuring as of April 1, 2015 FierceBiotech, 1 week ago DAIICHI SANKYO : Announces Organizational Restructuring as of April 1, 2015 4 Traders, 1 week ago
(Reuters) - The U.S. subsidiary of global pharmaceutical company Daiichi Sankyo Co Ltd has agreed to pay $39 million to the U.S. government and state Medicaid programs to settle claims it paid doctors kickbacks to prescribe its drugs, the Department of ...Reuters, 1 month ago
DAIICHI SANKYO : Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit
As the Mayo Clinic's 2012 published Benicar case study findings continue to be discussed, Ford & Associates Nationwide Legal Services, A.P.C., comments on these findings in wake of a January 2015 filed lawsuit: Verduzco v. Daiichi Sankyo, Inc. , ...4 Traders, 20 hours ago Mayo Clinic's Benicar Case Study Findings Prompts Commentary... San Francisco Chronicle, 12 hours ago
In January, Daiichi Sankyo announced FDA approval of edoxaban (Savaysa), a factor Xa inhibitor, for the reduction of stroke risk in patients with nonvalvular atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE) and ...Pharmacist.com, 5 days ago U.S. FDA approves Daiichi anti-clotting drug Reuters, 1 month ago
RnRMarketResearch.com adds "EpiCast Report Atrial Fibrillation - Epidemiology Forecast to 2023" report to its store. The report provides an overview of the risk factors, comorbidities, and the global and historical trends for AF in the eight major ...Wall Street Select, 1 day ago
For the millions of Americans living with type 2 diabetes, a combination of diet, exercise and medication can help them control the condition. But even those who are doing everything right to manage their diabetes may be at higher risk of developing ...The Suit Magazine, 8 hours ago
(Date:3/6/2015)... AbbVie (NYSE: ABBV ) will participate ... March 12, 2015. Richard A. Gonzalez , chairman ... and answer session at 8:30 a.m. Central time. ... be accessible through AbbVie,s Investor Relations Web site at ... will be available ...Bio-Medicine, 14 hours ago
/PRNewswire/ -- DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, will provide marketing, sales and regulatory services as well as distribution and logistics for lurasidone ...Yahoo! Finance, 1 day ago DKSH : expands Asian market for Sumitomo Dainippon Pharma 4 Traders, 1 week ago
on your WebpageAdd Widget >Get your members hooked!